Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSNM 2025 Drug List Coverage & PA Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the Blue Cross Blue Shield of New Mexico 2025 pharmacy drug list: which outpatient drugs are covered under the pharmacy benefit, tiering, specialty drugs, and prior authorization/step therapy processes for members and providers.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2025 Drug List (Pharmacy Benefit) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual drug list publication — no material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation when a drug line indicates 'PA' or exceeds listed quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120+Drug lines
    6Payment tiers
    manyFrequent QL entries
    multiplePA/SP flagged
    frequentNM flags present
    AccredoSpecialty contractor

    Coverage Criteria and Formulary Flags

    General pharmacy drug coverage

    Covered when plan documents and the BCBSNM Drug List indicate coverage and any Special Requirements (PA, ST, QL, AC, BH, NM, SP) are satisfied.

    Core conditions for pharmacy coverage: Drug is shown on the BCBSNM Drug List AND the member's benefit plan includes pharmacy coverage for that drug form (pharmacy vs medical benefit) AND any Special Requirements listed on the Drug List (e.g., PA, ST, QL, AC, BH, NM, SP) are satisfied

    Payment tiers and exceptions vary by plan; refer to member plan materials and the Special Requirements column on the Drug List.

    Formulary coverage flags

    Coverage and utilization-management flags shown on formulary entries determine prior authorization, quantity limits, specialty handling, and step-therapy requirements.

    Formulary listing: Each product is listed with a Drug Tier and one-or-more Requirement/Limits flags (examples: NM, QL, PA, SP, AC, BH, ST). These Requirement/Limits flags control coverage processing and member cost-sharing.

    When a flag is present on the Drug List, follow the associated operational rule (e.g., submit PA; adhere to QL; use specialty pharmacy for SP).

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2025 Drug List (Pharmacy Benefit) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual drug list publication — no material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation when a drug line indicates 'PA' or exceeds listed quantity limits.
    SourceLink
    On This Page
    Coverage Criteria and Formulary FlagsDrug Listings, Codes and Quantity DetailsPrior Authorization, Step Therapy, Documentation and Denial RisksInitial Therapy and Specialty Drug ControlsStep Therapy Rules and TablesQuantity Limits and Maintenance SupplySite of Care and Specialty Pharmacy RoutingAbbreviations and Key DefinitionsPolicy Background

    Formulary coverage entries

    Each formulary line shows the plan administrative stance and any quantity or program limits that apply to coverage processing.

    Formulary entry rule: Coverage for a listed drug follows the Drug Tier plus the Requirements/Limits notation on the line (e.g., NM, PA, AC, QL, SP). If Requirements/Limits include PA, a prior authorization must be obtained; if QL is present, dispensing cannot exceed the listed quantity/timeframe without exception; if SP is present the item may require specialty pharmacy handling.

    The Drug List is an item-level listing used to determine coverage and administrative controls; clinical diagnosis-level criteria are not included in the line items in this excerpt.

    Formulary coverage with quantity/program limits

    Coverage and limits are applied per product line when prescriptions conform to the listed Drug Tier and any program/quantity restrictions.

    Formulary entry application: Prescriptions are covered when they match a Drug List entry AND dispensing is within the listed Quantity Limit (QL) and other program constraints (SP, AC, ST) where present.

    Examples include oncology and specialty agents that carry QL and SP designations; refer to the specific line for the exact QL or pack limits.

    Product-specific coverage (list entries)

    Coverage stance and operational controls are product-specific; the following captures representative items and the controls that apply.

    Examples of covered products with limits: Selected contraceptives, estrogen products, antidiabetics, GLP-1/GIP agents, emergency glucagon, and other listed products are covered but may include Requirements/Limits such as AC, PA, QL, SP. For example: ANNOVERA is listed with AC and QL (1 ring/365 days); Vivelle-dot patches have QL (30 patches/30 days); OZEMPIC and other semaglutide presentations list PA and QL; MIFEPRISTONE (Korlym) lists PA, QL (120 tablets/30 days), SP.

    See each product line for the exact Requirement/Limits and quantity/time period.

    Drugs not shown on the BCBSNM 2025 Drug List are not covered. In addition, certain formulations or presentations may be excluded from coverage by plan design — for example, repackaged versions of marketed products, compounded preparations, and non–FDA‑approved drugs are not covered under the pharmacy benefit unless otherwise specified in the member’s plan materials. Refer to the member’s benefit plan and the Drug List for the definitive coverage determination and for any product‑specific Special Requirements (e.g., PA, QL, ST, AC, BH, NM).

    Most pharmacy benefits limit outpatient fills to a 30‑day supply, with some plans allowing up to a 90‑day supply for maintenance medications (conditions such as hypertension, diabetes, or hyperlipidemia). Prior authorization (noted as PA in the Special Requirements column) may be required for selected drugs; providers must obtain PA and submit supporting documentation when the Drug List indicates PA to avoid claim denial.

    The Drug List uses the Requirements/Limits field to indicate coverage controls for specific product presentations. Several azithromycin presentations and many antiretroviral combination products are listed with a Requirements/Limits code of NM in the formulary rows; when shown this status is applied at the product‑presentation level and may restrict coverage for that specific strength or formulation (e.g., azithromycin tabs/suspensions with Requirements/Limits = NM).

    Many antiretroviral and other combination products also show accompanying QL values (for example, QL (30 tablets/30 days)) and these quantity limits must be observed when dispensing. When a product line shows both NM and a QL entry the plan’s processing rules for that combination apply to claims for that exact presentation.

    This Drug List extract does not contain standalone medical exclusion statements for broad drug classes; instead, most entries specify operational controls (tier assignment and Requirements/Limits codes such as PA, QL, SP, AC, ST, and NM) that govern coverage processing for each listed product presentation. Where no Requirements/Limits are shown, coverage follows the member’s benefit plan and tier designation.

    Some individual entries are explicitly annotated with NM in the Requirements/Limits column (examples include certain vaccine presentations and some anti‑infective presentations listed elsewhere in the Drug List). Within this formulary extract NM functions as a product‑level utilization/coverage flag that can restrict coverage for that presentation; review the specific line item when adjudicating claims.

    Quantity limits are applied per product where noted (examples in the Drug List include QL (60 tablets/180 days) for some macrolide presentations and many other product‑specific QL values such as QL (30 tablets/30 days)). Requests exceeding the listed QL or lacking required PA/SP approvals may be denied per the plan’s adjudication rules.

    Coverage for each listed drug presentation is determined by three elements: (1) the drug appears on the BCBSNM Drug List; (2) the member’s benefit plan includes coverage for that drug form (pharmacy vs medical benefit and applicable tier); and (3) any Special Requirements shown on the Drug List are met. Operators processing claims should follow the Special Requirements codes on the product line — for example, PA (prior authorization), QL (quantity limit), SP (specialty program/specialty pharmacy), AC (administrative/ACA‑related coverage condition), and ST (step therapy) — when determining coverage eligibility.

    Prescribers and dispensing pharmacies must document indication, strength/formulation, and requested quantity consistent with the Drug List entry. For products marked PA or PA, QL (e.g., selected specialty cardiovascular and pulmonary agents and many high‑cost specialty drugs), submit the prior authorization and supporting clinical documentation before dispensing. For items with explicit QL values, dispense only up to the listed quantity for the specified time period unless an approved prior authorization or exception is obtained.

    If a drug is not shown on the Drug List, is a repackaged or non‑FDA product, or is a compounded product excluded by the member’s plan, it will not be covered. Members or providers may request Drug List exceptions or step‑therapy exceptions per the processes described in the benefit materials; expedited reviews are available when medically necessary as defined by plan procedures.

    Drug Listings, Codes and Quantity Details

    Listed drug products (by name/formulation)NDC | drug_name
    amoxicillinamoxicillin (trihydrate) various strengths and formulations
    amoxicillin/clavulanateamoxicillin & clavulanate various strengths and formulations (Augmentin)
    penicillin V potassiumpenicillin v potassium tab and suspension
    cefaclorcefaclor cap 250 mg, 500 mg
    cefadroxilcefadroxil tab/cap and susp
    azithromycinazithromycin formulations and tablets (Zithromax) with NM and QL notes
    clarithromycinclarithromycin formulations
    fidaxomicinDIFICID - fidaxomicin tab 200 mg and suspension
    doxycyclinedoxycycline hyclate/monohydrate various formulations
    omidacyclineNUZYRA - omadacycline tosylate tab 150 mg
    1–10 of 21
    1/3
    Formulary drug/product listingsmixed
    BIKTARVYbictegravir-emtricitabine-tenofovir af tab 30-120-15 mg, 50-200-25 mg
    CIMDUOlamivudine-tenofovir disoproxil fumarate tab 300-300 mg
    COMPLERAemtricitabine-rilpivirine-tenofovir df tab 200-25-300 mg
    DARUNAVIRdarunavir tab 600 mg; darunavir tab 800 mg
    DELSTRIGOdoravirine-lamivudine-tenofovir df tab 100-300-300 mg
    DESCOVYemtricitabine-tenofovir alafenamide fumarate tab (various strengths)
    DOVATOdolutegravir sodium-lamivudine tab 50-300 mg
    EDURANTrilpivirine hcl tab 25 mg; oral suspension
    EFAVIRENZefavirenz tabs and combination products (various)
    EMTRIVAemtricitabine caps/solution
    1–10 of 49
    1/5
    Drug listing (no billing codes provided)mixed
    N/AThis section contains drug names and formulations; no CPT/HCPCS/ICD codes are listed in these chunks.
    Formulary drug entries (brands and descriptors)mixed
    ELESTRINestradiol gel 0.06% (0.52 mg/0.87 gm metered-dose pump)
    Estrogelestradiol gel 0.06% (0.75 mg/1.25 gm metered-dose pump)
    Estraceestradiol tablet 0.5 mg, 1 mg, 2 mg
    Divigelestradiol transdermal gel (multiple strengths)
    Vivelle-dotestradiol transdermal patch (twice weekly strengths)
    Climaraestradiol transdermal patch (weekly strengths)
    Delestrogenestradiol valerate IM in oil (10, 20, 40 mg/ml)
    EVAMISTestradiol transdermal spray 1.53 mg/spray
    MENESTesterified estrogens tablets (various strengths)
    MENOSTARestradiol transdermal patch weekly 14 mcg/24hr
    1–10 of 32
    1/4
    REPATHA presentations (covered with PA/QL)mixedCovered
    140 mg/mlREPATHA - evolocumab subcutaneous soln prefilled syringe 140 mg/ml
    420 mg/3.5mlREPATHA PUSHTRONEX SYSTEM - evolocumab subcutaneous soln cartridge/infusor 420 mg/3.5ml
    Epinephrine autoinjectorsmixedCovered
    0.1 mg/0.1ml; 0.15 mg/0.15ml; 0.3 mg/0.3mlAUVI-Q - epinephrine solution auto-injector strengths
    Selected PA/QL designated formulationsmixedCovered
    5 mg/5mlCORLANOR - ivabradine hcl oral soln 5 mg/5ml
    0.6 mg/mlTYVASO - treprostinil inhalation solution 0.6 mg/ml
    Selected formulary product entriesmixed
    CAMZYOS - mavacamten cap 5 mgmavacamten capsule 5 mg
    CORLANOR - ivabradine hcl oral soln 5 mg/5mlivabradine oral solution 5 mg/5 ml
    ENTRESTO - sacubitril-valsartan tab 24-26 mg, 49-51 mg, 97-103 mgsacubitril-valsartan tablets various strengths
    Cardiac/PAH specialty productsmixed
    VYNDAMAX - tafamidis cap 61 mgtafamidis 61 mg capsule
    VYNDAQEL - tafamidis meglumine (cardiac) cap 20 mgtafamidis meglumine 20 mg capsule
    WINREVAIR - sotatercept-csrk for subcutaneous soln kitsotatercept subcutaneous solution kit
    Erectile dysfunction agentsmixedCovered
    sildenafil citrate tab 25 mg, 50 mg, 100 mg (Viagra)sildenafil tablets
    tadalafil tab 2.5 mg; 5 mg (Cialis); 10 mg, 20 mgtadalafil tablets various strengths
    avanafil tab 50 mg, 100 mg, 200 mg (Stendra)avanafil tablets
    Respiratory inhaled agentsmixedCovered
    ADVAIR HFA - fluticasone-salmeterol inhal aerosolfluticasone-salmeterol HFA inhaler
    ALBU/VENTOLIN HFA - albuterol sulfate inhal aerosol 108 mcg/actalbuterol HFA inhaler
    TRELEGY ELLIPTA - fluticasone-umeclidinium-vilanteroltriple combination inhaler
    Cystic fibrosis and specialty pulmonary agentsmixedCovered
    KALYDECO - ivacaftorivacaftor formulations
    ORKAMBI - lumacaftor-ivacaftorlumacaftor-ivacaftor formulations
    ALYFTREK - vanzacaftor-tezacaftor-deutivacaftortriple CF modulator formulations
    Cystic Fibrosis Modulatorsmixed
    ALYFTREKvanzacaftor-tezacaftor-deutivacaftor tab 4-20-50 mg; 10-50-125 mg (QL and SP noted)
    KALYDECOivacaftor tab 150 mg and packets (QL and SP noted)
    ORKAMBIlumacaftor-ivacaftor tabs/granules (QL and SP noted)
    SYMDEKOtezacaftor-ivacaftor & ivacaftor tabs (QL and SP noted)
    TRIKAFTAelexacaftor-tezacaftor-ivacaftor & ivacaftor formulations (QL and SP noted)
    Bowel Preparationsmixed
    Golytelypeg 3350-kcl-na bicarb-nacl-na sulfate for solution (various sizes) with AC or no limit
    PEG-PREPbisacodyl tab & PEG prep kit
    SUTABsodium sulfate tablets (bowel prep)
    Antiemetics/Constipation Agentsmixed
    EMENDaprepitant for oral suspension 125 mg (QL listed)
    ONDANSETRONondansetron formulations (tabs, soln, ODT)
    MOVANTIKnaloxegol oxalate tabs with QL
    Pancreatic Enzymes and Short Bowel Therapymixed
    CREONpancrelipase DR capsules (multiple strengths)
    ZENPEPpancrelipase DR capsules (multiple strengths)
    GATTEXteduglutide injection kit (PA, SP)
    Immunologic and Genitourinary Agentsmixed
    SKYRIZIrisankizumab cartridges (QL and SP noted)
    TREMFYAguselkumab prefilled syringe/auto-injector (QL, SP)
    MYRBETRIQmirabegron formulations (granules, ER tabs)
    Genitourinary topical and contraceptive productsmixed
    metronidazole vaginal gel 0.75%metronidazole vaginal gel 0.75%
    miconazole nitrate vaginal suppos 200 mgmiconazole nitrate vaginal suppos 200 mg
    NUVESSA metronidazole vaginal gel 1.3%NUVESSA - metronidazole vaginal gel 1.3%
    nonoxynol-9 gel 3%OPTIONS GYNOL II VAGINAL - nonoxynol-9 gel 3%
    PHEXXIPHEXXI - lactic acid-citric acid-potassium bitartrate gel 1.8-1-0.4%
    PREMARIN vaginal creamPREMARIN - estrogens, conjugated vaginal cream 0.625 mg/gm
    Genitourinary & related oral agentsmixed
    alfuzosin hcl tab er 24hr 10 mgalfuzosin hcl tab er 24hr 10 mg (Uroxatral)
    CYSTAGON - cysteamine cap 50 mg, 150 mgCYSTAGON - cysteamine bitartrate cap 50 mg, 150 mg
    dutasteride cap 0.5 mgdutasteride cap 0.5 mg (Avodart)
    ELMIRON - pentosan polysulfate 100 mgELMIRON - pentosan polysulfate sodium caps 100 mg
    FILSPARI - sparsentan tab 200 mg, 400 mgFILSPARI - sparsentan tab 200 mg, 400 mg
    Anxiolytics and antidepressantsmixed
    alprazolam tab er 24hr 0.5 mg - 3 mgalprazolam tab er 24hr 0.5 mg, 1 mg, 2 mg, 3 mg (Xanax xr)
    alprazolam tab 0.25 mg - 2 mgalprazolam tab 0.25 mg, 0.5 mg, 1 mg, 2 mg (Xanax)
    buspirone hcl tab 5 mg - 30 mgbuspirone hcl tab 5 mg, 10 mg, 15 mg, 30 mg
    diazepam conc 5 mg/mldiazepam conc 5 mg/ml
    fluoxetine hcl cap delayed release 90 mgFLUOXETINE DR - fluoxetine hcl cap delayed release 90 mg
    escitalopram oxalate tab 5 mg - 20 mgescitalopram oxalate tab 5 mg, 10 mg, 20 mg (Lexapro)
    desvenlafaxine succinate tab er 24hr 25-100 mgdesvenlafaxine succinate tab er 24hr 25 mg, 50 mg, 100 mg (Pristiq)
    Antipsychotics and mood stabilizersmixed
    aripiprazole oral solution 1 mg/mlaripiprazole oral solution 1 mg/ml
    aripiprazole orally disintegrating tab 10 mg, 15 mgaripiprazole orally disintegrating tab 10 mg, 15 mg
    aripiprazole tab 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mgaripiprazole tabs (Abilify)
    clozapine orally disintegrating tab 12.5 mg - 200 mgCLOZAPINE ODT - clozapine orally disintegrating tabs various strengths
    iloperidone tab various & titration packsFANAPT and FANAPT TITRATION PACKS
    quetiapine fumarate tabs (IR and XR) various strengthsquetiapine fumarate (Seroquel, Seroquel XR)
    risperidone tabs and ODT and solutionrisperidone formulations (Risperdal)
    brexpiprazole tab 0.25 mg - 4 mgREXULTI - brexpiprazole tabs
    Sample listed drug strengthsmixed
    300 mg, 400 mgquetiapine fumarate tab strengths (Seroquel)
    0.25 mg - 4 mgbrexpiprazole tab strengths (Rexulti)
    50 mg/mlclozapine suspension strength (Versacloz)
    1.5 mg - 6 mgcariprazine cap strengths (Vraylar)
    20 mg - 80 mgziprasidone cap strengths (Geodon)
    ADHD and wakefulness agentsmixed
    5 mg - 30 mgamphetamine-dextroamphetamine ER capsule strengths (Adderall XR)
    50 mg/3mlcaffeine citrate oral solution 60 mg/3ml
    10 mg - 200 mgarmodafinil/modafinil strengths (Nuvigil/Provigil)
    10 mg - 70 mglisdexamfetamine strengths (Vyvanse)
    Weight-management injectables and oral agentsmixed
    120 mgorlistat cap 120 mg (Xenical/Orlistat)
    0.25 mg/0.5ml - 1 mg/0.5mlsemaglutide injection strengths (Wegovy)
    2.5 mg/0.5ml - 15 mg/0.5mltirzepatide injection strengths (Zepbound)
    Sample listed drugsmixed
    MAVENCLAD - cladribine tab therapy pack 10 mg (5 tabs)Drug formulary line item as listed
    MAYZENT - siponimod fumarate tab 0.25 mgDrug formulary line item as listed
    Drugs with explicit QL/PA/SPmixed
    NUEDEXTA - dextromethorphan hbr-quinidine sulfate cap 20-10 mgRequirements: BH, PA, QL (60 capsules/30 days)
    PLEGRIDY - peginterferon beta-1a soln auto-injector 125 mcg/0.5mlRequirements: QL (2 pens/28 days), SP
    VUMERITY - diroximel fumarate capsule delayed release 231 mgRequirements: QL (120 capsules/30 days), SP
    Example quantity limits
    Azithromycin (example QL)Azithromycin tablets 250 mg and 500 mg — Requirements/Limits = NM; Quantity Limit = 60 tablets/180 days
    Itraconazole (example QL)Itraconazole cap 100 mg (Sporanox) — Requirements/Limits = NM; Quantity Limit = 120 capsules/30 days
    Fidaxomicin (note)DIFICID (fidaxomicin) tab 200 mg and suspension listed on formulary (QL not explicitly shown in cited excerpt) — check product line for any QL
    Common quantity limits
    Common tablet/capsule QLsFrequently used quantity limits include 30 tablets/30 days and 60 tablets/30 days for many oral products (examples: antiretroviral combos, select antibiotics).
    Packets/kits and inhalation QLsExamples include 30 packets/30 days, 1 kit/56 days (aztreonam lysine inhalation), and higher-volume inhalation presentations noted as mL-based limits (e.g., TOBI/ARIKAYCE entries).
    Large-volume oral suspensionsSome oral suspensions use mL-based QLs (examples: emtricitabine solution QL 720 mLs/30 days; itraconazole solution QL 1200 mLs/30 days).
    Specialty product QLsMany specialty or antiviral products are listed with QL where shown (e.g., EPCLUSA, HARVONI, SOVALDI — typical QL 30 tablets/30 days) and may carry SP designation.
    Quantity limits examples (oncology / specialty)
    Examples of clinic/oncology QLsHigh-cost oncology agents frequently have product-specific QLs (examples: BRAFTOVI encorafenib cap 75 mg QL = 180 capsules/30 days; IMBRUVICA oral suspension QL = 216 mLs/30 days).
    Specialty + QL pairingMany oncology and targeted therapies are designated SP (specialty) and include QL values to limit dispensing per period (see BOSULIF, BRUKINSA, CABOMETYX examples).
    Therapy-pack QLsSome oral therapy packs and pellet packs specify QLs by packet or pellet count (examples: HARVONI and SOVALDI QL = 30 packets/30 days; ROZLYTREK pellet pack counts are listed).

    Prior Authorization, Step Therapy, Documentation and Denial Risks

    Prior Authorization

    Obtain prior authorization when 'PA' is listed

    Prior authorization may be required for certain drugs; when commonly required the Drug List marks the product with 'PA' under the Special Requirements column. Providers must submit a prior authorization request and obtain approval before the medication will be covered when 'PA' is listed.

    • If a product line shows 'PA' the prescriber must submit a prior authorization prior to dispensing.
    • Some plans may require PA on additional medications beyond those noted; verify member benefit plan details.
    Prior Authorization

    PA and specialty handling for inhaled antibiotics

    Inhaled aminoglycoside products (e.g., TOBI, TOBI PODHALER, KITABIS PAK, ARIKAYCE) are annotated with PA, QL and specialty flags — providers must obtain prior authorization and follow specialty routing/quantity limits before dispensing.

    • TOBI/TOBI PODHALER — QL and SP indicated; PA required where listed.
    • ARIKAYCE — listed with QL and SP; PA must be obtained per the Drug List.
    Prior Authorization

    Prior authorization required for select products (e.g., PEGASYS)

    Certain listed products (for example, PEGASYS entries) are shown with 'PA' (and often 'SP'); providers must submit prior authorization for these products as indicated on the formulary line.

    • PEGASYS (peginterferon alfa-2a) entries explicitly list Requirements/Limits = PA, SP; PA is required before coverage.
    • Check the Special Requirements column on each product line for PA notation.
    Prior Authorization

    PA and specialty program requirements for specialty oncology drugs

    Many specialty oncology and high-cost agents are designated 'SP' and often require prior authorization and adhere to quantity limits (QL); providers must obtain PA and route dispensing through specialty pharmacy when indicated.

    • Examples: ALUNBRIG, ALECENSA, AKEEGA and other oncology agents list QL and SP and require PA or programmatic management.
    • Follow the Requirements/Limits (PA, QL, SP) shown on each drug line for authorization and site-of-care routing.
    Prior Authorization

    Obtain PA for testosterone products when listed

    Multiple testosterone products list 'PA' in the Requirements/Limits field; providers must obtain prior authorization before dispensing these testosterone formulations.

    • Examples include testosterone cypionate and testosterone enanthate injections and topical gels noted with Requirements/Limits = PA.
    • Dispense only after an approved prior authorization when 'PA' is present.
    Prior Authorization

    PA and QL required for select specialty/brand drugs

    Selected specialty or brand products (e.g., MOUNJARO, OZEMPIC, MIFEPRISTONE/Korlym, RYBELSUS) are marked with 'PA' and specific quantity limits; providers must submit prior authorization and adhere to the listed QL.

    • MOUNJARO — Requirements/Limits = PA, QL (e.g., 4 pens/180 days or 4 pens/28 days depending on strength).
    • OZEMPIC — Requirements/Limits = PA, QL (1 pen/28 days or volume-based QL as shown).
    • MIFEPRISTONE (Korlym) — Requirements/Limits = PA, QL (120 tablets/30 days), SP.
    Prior Authorization

    PA required for select GLP-1 and endocrine agents

    Certain GLP-1 receptor agonists and other specialty endocrine agents (e.g., TRULICITY, RYBELSUS) are labeled 'PA' (often with QL); prescribers must obtain prior authorization as indicated on the formulary entries.

    • TRULICITY — Requirements/Limits = PA, QL (4 pens/28 days).
    • RYBELSUS — Requirements/Limits = PA, QL (30 tablets/180 days for 3 mg; 30 tablets/30 days for 7/14 mg).
    Prior Authorization

    PA required for listed specialty drugs — verify PA/QL/SP

    Many specialty and high‑cost products across the Drug List show 'PA' in Requirements/Limits; providers must submit prior authorization requests and comply with any specialty pharmacy (SP) routing and quantity limits noted on the product line.

    • Verify PA, QL, and SP flags on each drug line prior to dispensing.
    • Specialty-designated items (SP) typically require specialty pharmacy distribution.
    Prior Authorization

    Follow BH prior authorization and controls for CNS agents

    Many behavioral health and central nervous system agents are designated 'BH' and some include 'ST' or 'PA'; providers must follow BH prior authorization processes and any quantity or step therapy controls listed.

    • Examples include aripiprazole, clozapine, risperidone formulations marked BH with QL and sometimes ST.
    • When 'BH' is listed, behavioral health prior authorization requirements apply.
    Step Therapy

    Adhere to step therapy ('ST') or submit exception

    Step therapy is indicated by 'ST' in the Special Requirements column for affected products; prescribers may submit step therapy exception requests and should document prior trials or clinical rationale when requesting an exception.

    • If 'ST' appears on a drug line, the member may need to trial preferred therapy first.
    • Step therapy exception requests are processed within three business days (or 24 hours if expedited for urgent conditions).
    Note

    SP-designated specialty drugs — follow PA/QL where shown

    Some specialty drugs are marked 'SP' and show QL limits; while SP indicates specialty handling, explicit step therapy sequences are not provided in this excerpt — providers must follow PA/QL/SP annotations for coverage and dispensing.

    • SP designation may imply specialty pharmacy routing and program requirements.
    • Where 'PA' is also listed, obtain authorization prior to dispensing.
    Note

    No explicit step sequences provided in this excerpt

    No explicit multi-step therapy sequences are specified in the provided Drug List excerpts; where step therapy applies it is indicated by 'ST' on the product line and must be followed or an exception requested.

    • Providers should not assume a specific step sequence unless 'ST' and the required prior step are specified on the formulary line.
    • Use the exception process if clinical reasons preclude the required step.
    Prior Authorization

    PA and SP noted for select pulmonary/PAH therapies

    Some specialty pulmonary and PAH therapies are marked 'SP' and 'PA' which may imply specialty pharmacy routing and prior authorization requirements; explicit step therapy rules are not present in these chunks, so obtain PA and follow specialty dispensing instructions.

    • ORENITRAM and TYVASO list PA and QL and are SP — obtain PA and adhere to QL prior to dispensing.
    • CAMZYOS, OPSUMIT and other PAH agents list PA/QL/SP — follow product-specific requirements.
    Billing Rule

    Honor starter pack / initiation quantity limits

    Starter packs and limited starter kit quantity limits are shown for some specialty products (e.g., MAYZENT starter packs, ZEPOSIA starter kits); providers must dispense starter packs only within the listed QL for initiation.

    • MAYZENT starter pack — Requirements/Limits = QL shown for starter pack; dispense per pack limit.
    • ZEPOSIA 7‑DAY STARTER PACK — Requirements/Limits = QL (7 capsules/180 days), SP.
    Denial Risk

    Non‑listed drugs and missing PA risk denial

    Drugs not shown on the Drug List are not covered under the pharmacy benefit; failure to obtain required prior authorization for drugs marked 'PA' can result in claim denial or lack of coverage.

    • Confirm the drug is on the Drug List and confirm any 'PA' requirement before dispensing.
    • If a PA is required and not approved, the claim may be denied and member may be financially responsible.
    Denial Risk

    Azithromycin QL/NM — risk of denial if limits not met

    Azithromycin formulations include 'NM' flags and quantity limits (e.g., tablet QL); claims that do not meet the listed Requirements/Limits or exceed QL may be subject to denial.

    • Azithromycin tablets show QL (e.g., 60 tablets/180 days); dispense per QL or obtain PA/documentation if seeking greater quantity.
    • Verify the specific presentation and Requirements/Limits on the formulary line.
    Denial Risk

    Denial risk for inhaled aminoglycosides without PA/within QL

    Inhaled aminoglycoside products (TOBI, TOBI PODHALER, KITABIS PAK, ARIKAYCE) list PA, QL and SP flags; absence of prior authorization or requests exceeding the QL may trigger denial.

    • TOBI nebu soln — QL (56 containers/56 days), SP; PA required where listed.
    • ARIKAYCE — QL (e.g., 235.2 mLs/28 days), SP — obtain PA and follow QL to avoid denial.
    Denial Risk

    PA/SP/AC flags can trigger denials if not satisfied

    Entries marked with PA, SP, or AC indicate requirements that can trigger prior authorization or special processing; failure to meet these listed controls can lead to benefit denial.

    • Products with 'AC' (administrative/approval criteria) may require supporting documentation at time of claim or PA submission.
    • When PA or SP is shown, obtain authorization and route dispensing accordingly to prevent denial.
    Denial Risk

    Exceeding QL or ignoring SP risks denial

    Claims that exceed quantity limits (QL) or request specialty program dispensing (SP) without authorization are subject to denial; providers should verify and adhere to QL values on each drug line.

    • Quantity limits are product‑specific (e.g., 30 tablets/30 days, 6 syringes/28 days); requests above these limits require PA or documentation.
    • Specialty drugs marked SP require specialty pharmacy handling; failing to use SP channel may affect coverage.
    Documentation Required

    PA and documentation required for select specialty agents (REPATHA, ORENITRAM)

    Medications listed with 'PA' or 'PA, QL' (for example, REPATHA/evolocumab, ORENITRAM) require prior authorization and documentation to support medical necessity; requests lacking required PA or supporting documentation risk denial.

    • REPATHA — Requirements/Limits = PA, QL (6 syringes/28 days) — obtain PA and document indication.
    • ORENITRAM — Requirements/Limits = PA, QL (300 tablets/30 days), SP — PA required prior to coverage.

    Initial Therapy and Specialty Drug Controls

    Specialty injectable/tablet initial coverage notes

    Coverage and utilization management for cardiovascular and related outpatient drugs are governed by the formulary annotations shown.

    Cardiovascular formulary rules: Each cardiovascular product is assigned a Drug Tier and may include Requirements/Limits such as PA, QL, or SP; when those flags are present prior authorization and/or quantity limits must be satisfied for coverage.

    Examples include REPATHA, CAMZYOS, ENTRESTO sprinkle, ORENITRAM and other PAH/cardiovascular agents that list PA/QL/SP.

    PA requirements for specialty/high-cost agents

    Prior authorization is expected for many specialty/high-cost cardiovascular and related agents listed with PA/QL/SP.

    PA-required specialty agents: Drugs annotated with PA (and often QL and SP) require a prior authorization request with supporting documentation of medical necessity before coverage will be approved.

    Examples in the formulary include REPATHA (PA, QL), CAMZYOS (PA, QL, SP), OPSUMIT (PA, QL, SP), ORENITRAM (PA, QL, SP).

    Operational initial therapy rules

    When no explicit clinical initial-therapy criteria are listed, operational controls govern coverage.

    Operational initial therapy rule: If a product's entry lists PA, the provider must obtain prior authorization before dispensing; if a QL is shown, dispense up to the QL for the specified time period; if SP is shown, the drug may require specialty pharmacy distribution.

    The Drug List entries in this excerpt do not include detailed clinical eligibility criteria — follow the Requirements/Limits annotations for operational actions.

    Initial therapy and dispensing controls

    Formulary initial coverage is determined by the listed Drug Tier and Requirements/Limits annotations.

    Initial coverage guidance: At therapy initiation, coverage is allowed when the prescription matches the listed Drug Tier and the Requirements/Limits (PA, QL, SP, AC, BH, ST) are satisfied; absent explicit clinical criteria, these operational controls are binding.

    Examples: CF modulators and other specialty agents list QL and SP values that limit initial dispensing until prior authorization and specialty routing are confirmed.

    Initial therapy controls

    Utilization controls at therapy initiation include prior authorization, behavioral health routing, specialty pharmacy, step edits, and starter-pack limits as indicated.

    Initial fill controls: Many products are managed with PA, QL, SP, BH or ST controls at initiation; providers must follow the listed Requirements/Limits for prior authorization, quantity dispensed, specialty routing, or step therapy requirements.

    Where step therapy (ST) or behavioral health (BH) is noted, prior steps or BH authorization must be met before coverage; starter packs and limited QLs may restrict initial dispensing.

    Step Therapy Rules and Tables

    Step therapy summaryImplication for provider / memberSource note
    Step Therapy (ST) is used when the benefit plan requires trial of a preferred, cost‑effective first‑line medication before coverage of the listed drug
    Providers may submit a step therapy exception request if the preferred first‑line drug is not appropriate; BCBSNM will notify the prescriber/member of the decision within three business days (or 24 hours for expedited reviews)
    If ST is commonly required for a medication it is noted with 'ST' in the Special Requirements column of the Drug List
    Flag / CodeMeaning / Effect on coverageExample from formulary
    AC (Approval Criteria)
    Indicates administrative/clinical criteria that must be met (may function like a step or documentation requirement prior to coverage)
    Some antiretroviral entries show 'AC' alongside NM and QL designations (see ARV listings)
    SP markerOperational effectFormulary example
    SP (Specialty) designation
    Product typically requires specialty pharmacy handling or program management; may be subject to PA and QL
    PALFORZIA and many oncology agents are listed with Requirements/Limits = SP
    Product group / exampleRequirementProvider action
    Testosterone products (e.g., methyltestosterone, testosterone cypionate, testosterone enanthate, topical gels/solutions)
    PA required for several testosterone presentations (listed as 'PA' in Requirements/Limits)
    Obtain prior authorization before dispensing; document indication and quantity per the formulary entry (QL values where listed)
    DrugRequirements/Limits showing STNote
    KERENDIA (finerenone)
    Requirements/Limits = QL (30 tablets/30 days), ST
    Step therapy (ST) is indicated for listed finerenone presentations; prior steps must be satisfied per the Drug List
    CNS / BH agent examplesRequirements/LimitsCoverage implication
    FETZIMA (levomilnacipran) and FETZIMA titration packs
    Requirements/Limits = BH, ST (behavioral health prior authorization plus step therapy)
    Step therapy must be met before coverage; BH designation indicates behavioral‑health prior authorization and QL apply
    Starter / kitQuantity limit or starter restrictionOperational note
    MAYZENT starter pack (siponimod) and MAVENCLAD therapy packs
    Requirements/Limits include starter‑pack QLs (e.g., MAYZENT starter pack noted; MAVENCLAD therapy packs have specific QL per pack) — limited supply during initiation
    Starter packs are quantity‑limited for initiation; subsequent dispensing follows standard QL and PA/SP designations as listed

    Quantity Limits and Maintenance Supply

    Maintenance medications & dispensing guidance
    Maintenance medication day supplyTypical coverage up to a 30-day supply; some plans permit up to a 90-day supply for maintenance medications
    Exception requestsMembers or prescribers may request Drug List or step therapy exceptions by calling the number on the member ID card; expedited reviews handled per plan timelines
    Documentation when exceeding QLPrescribers should document indication and quantity/duration to support requests that exceed listed QL
    Azithromycin tablet quantity limit
    Azithromycin tablets (250 mg & 500 mg)QL = 60 tablets
    Requirements/Limits flagListed presentations show Requirements/Limits = NM alongside the QL
    Time period60 tablets allowed per 180 days as listed for tablet strengths
    Itraconazole quantity limits
    Itraconazole capsule 100 mg (Sporanox)QL = 120 capsules per 30 days
    Oral solution presentationItraconazole oral solution also listed with a QL (1200 mL/30 days) where applicable
    Requirements/Limits contextEntry shows Requirements/Limits = NM with QL specified for capsule and solution forms
    Inhaled aminoglycoside examples and QLs
    ARIKAYCE (amikacin liposome inhalation)QL = 235.2 mL per 28 days (listed), SP/PA flags present
    TOBI PODHALER (tobramycin inhalation capsules)QL = 224 capsules per 56 days (listed), PA/SP indicated
    TOBI/TOBRAMYCIN nebulization solutionQL = 56 containers per 56 days (listed), PA/SP indicated
    Antiretroviral combination tablet limits
    Antiretroviral combination tablets (examples)QL = 30 tablets per 30 days where noted (e.g., BIKTARVY, DELSTRIGO, DESCOVY, DOVATO)
    Requirements/LimitsMany ARV entries show Requirements/Limits = NM and QL alongside tier designations
    Package/packet variantsSome ARV pellet/packet presentations list packet-based QLs (e.g., 28–90 packets/days) depending on product
    Multiple formulary QL examples
    Common QL examples (multiple entries)30 tablets/30 days; 60 tablets/30 days; 720 mLs/30 days; 1 kit/56 days; 90 tablets/30 days; 140 tablets/28 days; 360 packets/30 days
    Formulary contextThese QLs are applied across varied therapeutic classes (antivirals, oncology, inhaled agents, etc.) and are product-specific
    Adherence to QLPrescriptions exceeding QL may require documentation or prior authorization per policy guidance
    Linezolid quantity limits
    Linezolid oral suspension (Zyvox)QL = 600 mL per 180 days
    Linezolid tablets 600 mg (Zyvox)QL = 56 tablets per 180 days
    Formulary annotationEntries list QL with a 180-day period for some liquid and tablet presentations
    Linezolid tablet quantity limit
    Linezolid tablets 600 mg (Zyvox)QL = 56 tablets per 180 days
    Suspension QL referenceLinezolid suspension listed with a 600 mL/180 days QL in the same section
    Requirements/Limits contextEntries presented with NM or QL flags where applicable
    Vancomycin capsule quantity limit
    Vancomycin HCl capsules (Vancocin)QL = 120 capsules per 30 days
    Oral solution (Firvanq)Oral solution presentations listed separately; QL not specified for solution in this chunk
    Requirements/Limits flagEntry shows Drug Tier = NP with QL where noted
    Rifaximin (XIFAXAN) quantity limits
    XIFAXAN (rifaximin) 200 mgQL = 9 tablets per 30 days
    XIFAXAN (rifaximin) 550 mgQL = 60 tablets per 30 days
    Product-specific QLsDifferent strengths have distinct QL values as listed in the formulary
    REPATHA quantity limits
    REPATHA prefilled syringeQL = 6 syringes per 28 days (requires PA)
    REPATHA PUSHTRONEX cartridge/infusorQL = 2 cartridges per 30 days (requires PA)
    Specialty/PA contextREPATHA entries include PA and SP annotations in the formulary
    ALYFTREK quantity limits
    ALYFTREK (example strength)QL = 84 tablets per 28 days
    Alternate strengthQL = 56 tablets per 28 days for other strength
    Specialty designationProduct entries include SP alongside QL in the formulary
    ORKAMBI quantity limits
    ORKAMBI (lumacaftor‑ivacaftor)QL = 120 tablets per 30 days
    Packet presentationsGranule/packet forms shown with packet-based QLs (e.g., 60 packets/30 days)
    Specialty handlingORKAMBI entries are specialty-designated (SP) in the formulary
    TRIKAFTA quantity limits
    TRIKAFTA (packets)QL = 56 packets per 28 days (packet presentation) or 90 tablets per 30 days for certain tablet packs, SP
    Product presentationsTRIKAFTA is listed with both packet- and tablet-based QLs depending on formulation
    Specialty designationCF modulators carry SP flags indicating specialty pharmacy handling
    SKYRIZI cartridge quantity limit
    SKYRIZI cartridge 180 mgQL = 1 cartridge per 56 days, SP
    SKYRIZI 360 mg cartridgeQL = 2.4 mL per 56 days (alternate presentation listed)
    Specialty handlingCartridge presentations are specialty-designated and have cartridge-based QLs
    Selected BH, PA, and SP product QLs
    NUEDEXTA (dextromethorphan/quinidine) 20/10 mgQL = 60 capsules per 30 days; Requirements/Limits include BH and PA
    PLEGRIDY (peginterferon beta‑1a)QL = 2 pens or 2 syringes per 28 days; SP
    VUMERITY (diroximel fumarate)QL = 120 capsules per 30 days; SP

    Site of Care and Specialty Pharmacy Routing

    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Key Definitions

    Policy Background

    Specialty drugs are medications used to treat complex or chronic conditions (examples in the Drug List include agents for hepatitis, hemophilia, multiple sclerosis, rheumatoid arthritis, cystic fibrosis and pulmonary arterial hypertension). These products may be oral, topical, or injectable and often require additional handling, patient support, or specialty pharmacy distribution. Medications administered by a health care professional (in‑office or hospital) may be covered under the medical benefit rather than the pharmacy benefit; check the member’s plan materials to determine the appropriate benefit and any specialty program or prior authorization requirements. The Drug List is maintained by a clinical review committee and is updated periodically; providers should consult bcbsnm.com or MyPrime for the most current listing and coverage rules.